PATENT: CV01185K1X US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

			X			
Applicant(s	s): Chacl	kalamannil, <i>et al</i> .		Group Art Unit:	1617	
Application No.: 10/705,282				Examiner:	Carlic K. Huynh	
Filed:	Nover	mber 10, 2003	Confirmation No.	: 4919		
For:		ods of Use of obin Receptor Antagonists	x	Date:	May 12, 2008	
		INFORMATION DISCLO	SURE	<u>STATEMENT</u>		
Commissio P.O. Box 1 Alexandria, Mailstop:	450 VA 22:					
Sir:						
published prelated U.S Examiner is applications request.	eatent apoli S. Appli s believ s, copies	the above-identified patent applications, copy(ies) of these cation No(s) filled to have ready access to sof these documents are not have the contract of the contract	docume ed the cite nerewith	ents 🛛 are enclos , respected U.S. patents an	ed were filed in trively. Since the published patent	
(b)	No fee is believed to be due because:					
		This Information Disclosure Statement is being submitted concurrent with the filing of the above-identified application; or				
		This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; or				
	\boxtimes	This Information Disclosure with a Request for Continue	Staten	nent is being subr		
		This Information Disclosure mailing of a first Office Actio	Staten on the	nent is being subr merits.	mitted prior to the	
(c)	The state of the s	This Information Disclosure mailing date of any final a otherwise closes prosecution	ction, no	ment is being sub otice of allowance,	mitted before the or an action that	
		Each item of information Statement was first confice in a counterp	ited in a	communication fro	m a foreign patent	

Application No. 10/705,282 Information Disclosure Statement Page 2 of 2

			months prior to the filing of this Information Disclosure Statement; or		
			No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; or		
			The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.		
	(d) This Information Disclosure Statement is being submitted on or befo payment of the issue fee; and:				
			Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or		
			No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filling of this Information Disclosure Statement; and		
			The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.		
The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365.					
			Respectfully submitted,		
Scheri Patent 2000 G Kenilwo	May 12, 200 ng-Plough (Department, alloping Hill orth, NJ 070 ile No.: (908	orporation K-6-1, 19 Road 33-0530	90 Reg. No.: 43,041 Attorney of Record Telephone No.: (908) 298-2960		